New Delhi, May 22 (PTI) Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat asthma.

The company has received final approval from the US Food and Drug Administration (USFDA) to market Theophylline extended-release tablets (300 mg and 450 mg), the drug firm said in a statement.

Also Read | Rajiv Gandhi Death Anniversary 2024: Quotes by Rajiv Gandhi To Share in Memory of the Former Indian Prime Minister.

Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD).

The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, the drugmaker said.

Also Read | Anti Terrorism Day 2024 in India Date, History and Significance: Know About the Day That Raises Awareness About the Dangers of Terrorism.

As per the IQVIA MAT data, Theophylline extended-release tablets (300 mg and 450 mg) had annual sales of USD 12.6 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)